Cell Origin Biotech (hangzhou) Co., Ltd.

This early-stage study is testing a new cell-based therapy called SY001 in people with advanced ovarian or pancreatic cancer that has not responded to prior treatments. The main goals are to find a safe dose, see how the body handles the treatment, and check for any early signs t…